Mazdutide
InvestigationalAlso known as: IBI362, LY3305677, Xinermei
A dual GLP-1 and glucagon receptor agonist developed by Innovent/Eli Lilly. NMPA approved in China (2025) for obesity. GLORY-1 trial showed 14.3% weight loss at 48 weeks. DREAMS-3 head-to-head trial demonstrated superiority vs semaglutide for combined diabetes + obesity outcomes.
Research Statistics
Phase 3 GLP-1/glucagon dual agonist with strong China-led trial program; trials primarily China-based so global coverage limited, but GLP-1R/GCGR dual mechanism well-characterized.
Research Dossier
Overview
What is Mazdutide and what does the research say?
Mechanism of Action
Mazdutide is a dual GLP-1 and glucagon receptor agonist with robust Phase 3 clinical trial data. Its mechanisms are well-characterized in human studies.
How It Works (Simplified)
GLP-1 receptor activation in the brain increases satiety signals, reducing hunger and food intake similar to semaglutide.
Glucagon receptor activation directly stimulates hepatic fatty acid oxidation, burning fat stored in the liver.
Glucose-dependent insulin secretion improves blood sugar control without causing hypoglycemia when blood sugar is normal.
Glucagon increases metabolic rate and calorie burning, contributing to weight loss beyond appetite reduction alone.
Scientific Pathways
GLP-1 Receptor Pathway (Appetite & Glucose)
Mazdutide → GLP-1R activation → Brain satiety centers → Reduced food intake
→ Pancreatic beta cells → Insulin secretion
→ Gastric emptying → Delayed nutrient absorptionGlucagon Receptor Pathway (Liver & Metabolism)
Mazdutide → GCGR activation → Hepatic fatty acid oxidation → Liver fat reduction
→ Gluconeogenesis modulation → Balanced by insulin
→ Thermogenesis → Increased energy expenditureKey Research: Ji L et al. (NEJM 2025) demonstrated 14.3% weight loss and 80% liver fat reduction in GLORY-1 trial. PMID:39661467
Important Limitations
- Currently only approved in China (NMPA); not yet FDA approved
- Long-term safety data beyond 48 weeks is limited
- Head-to-head data vs tirzepatide not yet available
- Optimal patient selection criteria still being refined
- GI tolerability requires careful dose titration
Evidence-Chained Benefits
Evidence-Chained Benefits
Research findings linked to mechanisms and clinical outcomes
What to Expect
Timeline based on observations from published studies. Individual responses may vary.
Initial dose titration period. Nausea and GI effects most common during this phase. Early appetite suppression and reduced food intake typically begin within days of first dose.
Continued dose escalation to target dose. Steady weight loss averaging 1-2% body weight per month. Blood glucose improvements measurable. GI side effects typically diminish.
Maintenance dosing established. Weight loss continues at consistent rate. Liver fat reduction becomes measurable on imaging. HbA1c improvements reach clinically significant levels.
Peak efficacy period. GLORY-1 showed 14.3% total body weight loss at 48 weeks. Liver fat reduction of 80% in affected patients. Sustained glycemic control.
Research-Based Observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Quality Checklist
Visual indicators to help evaluate Mazdutide product quality
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (6 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Peptide Interactions
Known and theoretical interactions when combining Mazdutide with other peptides. Based on published research and mechanistic considerations.
BPC-157
CautionBoth affect GI function. Mazdutide slows gastric emptying while BPC-157 is gastroprotective. Monitor GI symptoms if combined; interaction data unavailable.
Semaglutide
AvoidBoth are GLP-1 receptor agonists. Combining would duplicate mechanisms and increase risk of severe GI adverse effects and hypoglycemia. No clinical rationale for combination.
Tirzepatide
AvoidBoth target GLP-1 receptors with overlapping mechanisms. Combining incretin therapies is contraindicated due to additive effects and safety concerns.
Survodutide
AvoidBoth are dual GLP-1/glucagon receptor agonists with identical mechanisms. Combination would be redundant and potentially dangerous.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
References
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
Methodology Note
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Mazdutide
Mazdutide Calculators
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium, NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111, Oral Amycretin, Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191, hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833, NN9838, ZP8396
A long-acting amylin analog developed by Novo Nordisk for weight management. Currently in Phase 3 trials as CagriSema (combination with semaglutide). Phase 2 data shows up to 22-25% weight loss when combined with semaglutide, potentially exceeding tirzepatide efficacy.
CagriSema
Cagrilintide-Semaglutide, NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. Phase 1b results showed 18.8% placebo-adjusted weight loss at 24 weeks, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.